Esophageal Cancer
Conditions
Keywords
Esophageal Cancer, Concurrent chemoradiation, Immunotherapy, SHR-1210, Apatinib
Brief summary
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
Interventions
DRUGSHR-1210
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
RADIATIONIMRT or VMAT
The IMRT or VMAT technique was used in our study.
DRUGApatinib
Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. age:18-75 years, male or female. 2. Histologically confirmed primary Squamous Cell Carcinoma of the Esophagus,Local advanced esophageal cancer diagnosed by pathology and imaging,clinical stage T3-4N0M0, T1-4N+M0,Ⅱ-Ⅳa. 3. Pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of the concurrent use of chemotherapy with radiotherapy. 4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. 5. ECOG 0-1. 6. Adequate organ function. 7. Life expectancy of greater than 6 months. 8. Patient has given written informed consent.
Exclusion criteria
1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy. 2. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation. 3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ); 4. Subjects with any active autoimmune disease or history of autoimmune disease \- Page 4 of 4 \[DRAFT\] - 5. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; 6. Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); 7. Received a live vaccine within 4 weeks of the first dose of study medication. 8. Pregnancy or breast feeding. 9. Decision of unsuitableness by principal investigator or physician-incharge.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events (AE), Serious Adverse Event(SAE) Adverse events | Through study completion, an average of half a year] | Incidence of Treatment-Emergent Adverse Events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Through study completion, an average of 1 year | Objective Response Rate |
| PFS | 1year and 3years | Progression-Free Survival |
| OS | 1year and 3years | overall survival |
Countries
China
Outcome results
None listed